| Title: | Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation : An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study) |
| Authors: | Cho, Kyu Yong Browse this author |
| Nomoto, Hiroshi Browse this author |
| Nakamura, Akinobu Browse this author →KAKEN DB |
| Kawata, Shinichiro Browse this author |
| Sugawara, Hajime Browse this author |
| Takeuchi, Jun Browse this author |
| Nagai, So Browse this author |
| Tsuchida, Kazuhisa Browse this author |
| Omori, Kazuno Browse this author |
| Yokoyama, Hiroki Browse this author |
| Manda, Naoki Browse this author |
| Kurihara, Yoshio Browse this author |
| Aoki, Shin Browse this author |
| Atsumi, Tatsuya Browse this author →KAKEN DB |
| Miyoshi, Hideaki Browse this author →KAKEN DB |
| Keywords: | continuous glucose monitoring |
| DPP-4 inhibitor |
| randomized trial |
| SGLT2 inhibitor |
| type 2 diabetes |
| Issue Date: | Mar-2020 |
| Publisher: | John Wiley & Sons |
| Journal Title: | Diabetes, Obesity and Metabolism |
| Volume: | 22 |
| Issue: | 3 |
| Start Page: | 458 |
| End Page: | 462 |
| Publisher DOI: | 10.1111/dom.13879 |
| Abstract: | This multicentre, prospective, randomized, open-label, blinded-endpoint, parallel-group, short-term (4-5 weeks) controlled trial was conducted to investigate the superiority of the effect of reducing mean amplitude of glycaemic excursions (MAGE) during meal tolerance tests (MTTs) for the combination of dipeptidyl peptidase-4 (DPP-4) inhibitor and sodium-glucose co-transporter-2 (SGLT2) inhibitor compared with SGLT2 inhibitor monotherapy. Ninety-nine patients with type 2 diabetes who were taking teneligliptin (20 mg/d) were randomized to one of the following two groups: those who switched to 100 mg/d of canagliflozin (SWITCH group) or those who added 100 mg/d of canagliflozin (COMB group). MAGE in the COMB group was significantly decreased compared with that in the SWITCH group (COMB 117.5 +/- 39.8 to 92.2 +/- 28.0 mg/dL vs SWITCH 110.7 +/- 29.8 to 104.2 +/- 27.6 mg/dL; P<0.01). Mean blood glucose decreased significantly during MTTs in both groups, although the extent of the reduction was significantly greater in the COMB group (COMB 142.3 +/- 28.7 to 119.5 +/- 25.1 mg/dL vs SWITCH 146.4 +/- 25.5 to 135.5 +/- 22.4 mg/dL; P < 0.01). SGLT2 inhibitor combined with DPP-4 inhibitor therapy strongly reduced glycaemic fluctuation compared with SGLT2 inhibitor monotherapy. |
| Rights: | https://creativecommons.org/licenses/by-nc/4.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/76814 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
